BioNTech (BNTX) Stock Analysis

November 11, 2026

This is a peer-relative look at BioNTech (BNTX): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

BioNTech (BNTX) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile fields for BioNTech (BNTX)
Profile Item	BNTX
Name	BioNTech SE American Depositary Share
Country/Region	Germany
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	21.70 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	October 10, 2019
Security Type	ADR

Price Performance

Cumulative Growth

BNTX

GSPC

BioNTech (BNTX) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioNTech (BNTX) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioNTech (BNTX) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Total Return (1Y)	-14.78%	24.62%
Total Return (3Y, Annualized)	-3.99%	20.37%
Total Return (5Y, Annualized)	-17.02%	-4.02%

Risk Profile

Drawdown History

BNTX

GSPC

BioNTech (BNTX) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioNTech (BNTX) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Volatility (1Y, Annualized)	47.44%	66.36%
Beta (5Y)	1.30	0.93
Max Drawdown (5Y)	-78.10%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. BNTX is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Sharpe Ratio (1Y)	-0.40	0.36
Sortino Ratio (1Y)	-0.59	0.58

Profitability

ROE (TTM)

BioNTech (BNTX) has negative ROE of -8.14%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Group distribution

Max: 109.18%
Q3: 6.23%
BNTX: -8.14%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
BNTX: -8.14%
ABBV: --

Where BioNTech (BNTX) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

BioNTech (BNTX) has negative net margin of -60.87%. The trailing period ended in a net loss, so the bottom-line conversion read is a warning rather than a profitability strength.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Group distribution

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
BNTX: -60.87%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%
BNTX: -60.87%

Where BioNTech (BNTX) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

BioNTech (BNTX) turns 30.28% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Group distribution

Max: 83.12%
BNTX: 30.28%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
BNTX: 30.28%
AZN: 29.57%
JNJ: 25.74%

Where BioNTech (BNTX) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
ROE (TTM)	-8.14%	-26.66%
ROA (TTM)	-4.04%	-12.50%
Net Margin (TTM)	-60.87%	0.00%
Operating Margin (TTM)	30.28%	0.00%
Gross Margin (TTM)	76.73%	37.87%

Growth

Revenue Growth

BioNTech (BNTX) grew revenue 4.32%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

BioNTech (BNTX): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

No usable EPS growth is available for BioNTech (BNTX) this period, so the earnings-momentum read is skipped.

BioNTech (BNTX) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Revenue Growth (YoY)	4.32%	11.45%
Revenue Growth (3Y CAGR)	-45.06%	9.94%
EPS Growth (YoY)	--	4.28%
EPS Growth (3Y CAGR)	--	4.17%

Financial Strength

Current Ratio (MRQ)

BioNTech (BNTX) has current ratio of 8.55, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Group distribution

Max: 25.13
Q3: 12.13
BNTX: 8.55
Median: 5.52
Q1: 2.47
Min: 0.10

Largest peers

BNTX: 8.55
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where BioNTech (BNTX) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

BioNTech (BNTX) has debt-to-equity ratio of 0.02, in the lower-leverage quartile for its industry. Borrowing is modest relative to equity compared with most peers, which can leave more flexibility through a cycle.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Group distribution

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
BNTX: 0.02
Min: 0.00

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
BNTX: 0.02
ABBV: --

Where BioNTech (BNTX) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Current Ratio (MRQ)	8.55	5.52
Debt / Equity (MRQ)	0.02	0.15
Net Debt / EBITDA	--	1.08

Dividends

Dividend Yield (TTM)

BioNTech (BNTX) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BNTX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
BNTX: 0.00%

Where BioNTech (BNTX) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

BioNTech (BNTX) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BNTX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
BNTX: 0.00%

Where BioNTech (BNTX) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

No usable P/E ratio is available for BioNTech (BNTX) this period, so the trailing-earnings valuation read is skipped.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BNTX: --

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
BNTX: --

BioNTech (BNTX) doesn’t report P/E ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/S Ratio (TTM)

BioNTech (BNTX) trades at 8.96 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Group distribution

Max: 58.18
Q3: 25.77
BNTX: 8.96
Median: 7.30
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
BNTX: 8.96
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63

Where BioNTech (BNTX) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

BioNTech (BNTX) trades at 1.09 on P/B ratio, in the lower book-value quartile for its industry. Investors are paying less for the balance-sheet equity than they pay for most peers, with returns on that equity still central to the read.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Group distribution

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BNTX: 1.09
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
BNTX: 1.09
ABBV: -112.34

Where BioNTech (BNTX) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

BioNTech (BNTX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BNTX	Industry group median
P/E Ratio (TTM)	--	26.69
P/S Ratio (TTM)	8.96	7.30
P/B Ratio (MRQ)	1.09	3.25
Free Cash Flow Yield (TTM)	-7.34%	-1.66%